Status:
COMPLETED
Erythropoietin Therapy for Subarachnoid Hemorrhage
Lead Sponsor:
University of Cambridge
Collaborating Sponsors:
Hoffmann-La Roche
Roche Foundation of Anemia Research (RoFAR, Switzerland)
Conditions:
Aneurysmal Subarachnoid Hemorrhage
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
ABSTRACT: Delayed ischemic deficits (DID) and strokes caused by low cerebral blood flow (CBF) are major sources of poor outcome following aneurysmal subarachnoid hemorrhage (SAH). DID are often accom...
Detailed Description
BACKGROUND: 1. Delayed ischaemia deficits in subarachnoid haemorrhage Seven thousand patients suffer SAH each year within the UK with young adults (\<55 years) being equally affected. Cerebral va...
Eligibility Criteria
Inclusion
- Adult patients (\>= 18 years)
- Aneurysmal subarachnoid hemorrhage
Exclusion
- Uncontrolled systemic hypertension (systolic blood pressure \> 220 mmHg)
- Erythrocytosis vera
- Concurrent erythropoietin therapy
- Negative angiography
- Subarachnoid hemorrhage more than 7 days
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00140010
Start Date
April 1 2005
End Date
March 1 2007
Last Update
May 20 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurosurgery, Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom, CB2 2QQ